Malignant Bladder Neoplasm — Trials

Malignant Bladder Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,510 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 346
Recruiting: 177
Ph III recruiting: 23
Growth YoY: +17.9%
Industry share: 21%
Top sponsor: National Cancer Institute (NCI)
Termination share: 31.3%
Trials / 1,000 deaths: 20 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (179)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03801278	An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer(FPA144)	no longer available	—	—	Five Prime Therapeutics, Inc.INDUSTRY	0	Dec 13, 2021	clinicaltrials
NCT01956253	Single Subject Neratinib in Bladder Cancer (NRR)	no longer available	—	—	UNC Lineberger Comprehensive Cancer CenterOTHER	1	Mar 14, 2017